Chantal Quinten1, Corneel Coens2, Irina Ghislain3, Efstathios Zikos4, Mirjam A G Sprangers5, Jolie Ringash6, Francesca Martinelli7, Divine E Ediebah8, John Maringwa9, Bryce B Reeve10, Eva Greimel11, Madeleine T King12, Kristin Bjordal13, Hans-Henning Flechtner14, Joseph Schmucker-Von Koch15, Martin J B Taphoorn16, Joachim Weis17, Hans Wildiers18, Galina Velikova19, Andrew Bottomley20. 1. European Centre for Disease Prevention and Control, Surveillance and Response Support, Epidemiological Methods Unit, Tomtebodavagen 11A, 171 83 Stockholm, Sweden. Electronic address: chquinten@gmail.com. 2. Quality of Life Department, EORTC Headquarters, Avenue E. Mounier 83/11, 1200 Brussels, Belgium. Electronic address: corneel.coens@eortc.be. 3. Quality of Life Department, EORTC Headquarters, Avenue E. Mounier 83/11, 1200 Brussels, Belgium. Electronic address: irina.ghislain@eortc.be. 4. Quality of Life Department, EORTC Headquarters, Avenue E. Mounier 83/11, 1200 Brussels, Belgium. Electronic address: efstathios.zikos@eortc.be. 5. Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Electronic address: m.a.sprangers@amc.uva.nl. 6. The Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada. Electronic address: jolie.ringash@rmp.uhn.on.ca. 7. Quality of Life Department, EORTC Headquarters, Avenue E. Mounier 83/11, 1200 Brussels, Belgium. Electronic address: francesca.martinelli@eortc.be. 8. Clinical Research, Abbott Vascular International BVBA, Park Lane, Culliganlaan 2B, 1831 Diegem, Belgium. Electronic address: ediebahdivine@gmail.com. 9. Quantative Solutions, Parkstraat 1b, 4818 SJ Breda, The Netherlands. Electronic address: j.maringwa@wequantify.com. 10. Gillings School of Global Public Health, University of North Caroline at Chapel Hill, 1101-D Mc Gavran-Greenberg Building, 135 Dauer Drive, CB 7411, Chapel Hill, NC 27599-7411, United States. Electronic address: bbreeve@email.unc.edu. 11. Medical University Graz, Auenbruggerplatz 14, AT 8036 Graz, Austria. Electronic address: elfriede.greimel@klinikum-graz.at. 12. Cancer Australia Chair in Cancer Quality of Life, School of Psychology and Sydney Medical School, University of Sydney, New South Wales 2006, Australia. Electronic address: madeleine.king@sydney.edu.au. 13. Research Support Services, Oslo University Hospital, Sogn Arena, Pb 4950 Nydalen, NO-0424 Oslo, Norway. Electronic address: kbj@ous-hf.no. 14. Child and Adolescent Psychiatry and Psychotherapy, Leipzigerstrasse 44, University of Magdeburg, 39120 Magdeburg, Germany. Electronic address: hans-henning.flechtner@med.ovgu.de. 15. Medical Ethics, Philosophical Faculty, University of Regensburg, Universitaetstrasse 31, 93040 Regensburg, Germany. Electronic address: joseph.schmucker-von-koch@psk.uni-regensburg.de. 16. VU Medical Center, De Boelelaan 1118, 1081 HZ Amsterdam, The Netherlands; Medical Center Haaglanden, P.O. Box 432, Lijnbaan 2, NL 2501 CK The Hague, The Netherlands. Electronic address: m.taphoorn@mchaaglanden.nl. 17. Tumor Biology Center University Hospital Freiburg, Breisacherstrasse 117, 79106 Freiburg, Germany. Electronic address: weis@tumorbio.uni-freiburg.de. 18. Department of General Medical Oncology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Electronic address: hans.wildiers@uzleuven.be. 19. Faculty of Medicine and Health, Leeds Institute of Cancer & Pathology, University of Leeds, Bexley Wing (Level 4), St James's Hospital, Beckett Street, Leeds LS9 7TH, UK. Electronic address: G.Velikova@leeds.ac.uk. 20. Quality of Life Department, EORTC Headquarters, Avenue E. Mounier 83/11, 1200 Brussels, Belgium. Electronic address: andrew.bottomley@eortc.be.
Abstract
BACKGROUND: Cancer incidence increases exponentially with advancing age, cancer patients live longer than in the past, and many new treatments focus on stabilizing disease and HRQOL. The objective of this study is to examine how cancer affects patients' HRQOL and whether their HRQOL is age-dependent. METHODS: Data from 25 EORTC randomized controlled trials was pooled. EORTC QLQ-C30 mean scores for the cancer cohort and five general population cohorts were compared to assess the impact of cancer on patients' HRQOL. Within the cancer cohort, multiple linear regressions (two-sided level P-value = 0.05 adjusted for multiple testing.) were used to investigate the association between age and HRQOL, adjusted for gender, WHO performance status (PS), distant metastasis and stratified by cancer site. A difference of 10 points on the 0-100 scale was considered clinically important. RESULTS: Cancer patients generally have worse HRQOL compared to the general population, but the specific HRQOL domains impaired vary with age. When comparing the cancer versus the general population, young cancer patients had worse financial problems, social and role functioning, while the older cancer groups had more appetite loss. Within the cancer cohort, HRQOL was worse with increasing age for physical functioning and constipation, and better with increasing age for social functioning, insomnia and financial problems (all p < 0.05). CONCLUSION: HRQOL is impaired in cancer patients compared to the general population, but the impact on specific HRQOL domains varies by age. Within the cancer population, some HRQOL components improve with age while others deteriorate. Optimal care for older cancer patients should target HRQOL domains most relevant to this population.
BACKGROUND: Cancer incidence increases exponentially with advancing age, cancer patients live longer than in the past, and many new treatments focus on stabilizing disease and HRQOL. The objective of this study is to examine how cancer affects patients' HRQOL and whether their HRQOL is age-dependent. METHODS: Data from 25 EORTC randomized controlled trials was pooled. EORTC QLQ-C30 mean scores for the cancer cohort and five general population cohorts were compared to assess the impact of cancer on patients' HRQOL. Within the cancer cohort, multiple linear regressions (two-sided level P-value = 0.05 adjusted for multiple testing.) were used to investigate the association between age and HRQOL, adjusted for gender, WHO performance status (PS), distant metastasis and stratified by cancer site. A difference of 10 points on the 0-100 scale was considered clinically important. RESULTS: Cancer patients generally have worse HRQOL compared to the general population, but the specific HRQOL domains impaired vary with age. When comparing the cancer versus the general population, young cancer patients had worse financial problems, social and role functioning, while the older cancer groups had more appetite loss. Within the cancer cohort, HRQOL was worse with increasing age for physical functioning and constipation, and better with increasing age for social functioning, insomnia and financial problems (all p < 0.05). CONCLUSION: HRQOL is impaired in cancer patients compared to the general population, but the impact on specific HRQOL domains varies by age. Within the cancer population, some HRQOL components improve with age while others deteriorate. Optimal care for older cancer patients should target HRQOL domains most relevant to this population.
Authors: Jennifer L Spiegel; Yiannis Pilavakis; Bernhard G Weiss; Martin Canis; Christian Welz Journal: Eur Arch Otorhinolaryngol Date: 2019-05-27 Impact factor: 2.503
Authors: Andreas Hinz; Joachim Weis; Hermann Faller; Elmar Brähler; Martin Härter; Monika Keller; Holger Schulz; Karl Wegscheider; Uwe Koch; Kristina Geue; Heide Götze; Anja Mehnert Journal: Support Care Cancer Date: 2018-04-26 Impact factor: 3.603
Authors: Kathryn L Taylor; George Luta; Richard M Hoffman; Kimberly M Davis; Tania Lobo; Yingjun Zhou; Amethyst Leimpeter; Jun Shan; Roxanne E Jensen; David S Aaronson; Stephen K Van Den Eeden Journal: Transl Behav Med Date: 2018-03-01 Impact factor: 3.046
Authors: Inger Utne; Bruce A Cooper; Christine Ritchie; Melisa Wong; Laura B Dunn; Borghild Loyland; Ellen Karine Grov; Marilyn J Hammer; Steven M Paul; Jon D Levine; Yvette P Conley; Kord M Kober; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2020-08-03 Impact factor: 2.398